A Multicenter, Randomized, Open, Parallel-controlled Clinical Trial to Compare the Efficacy and Safety of IDegAsp BID and IDegAsp QD+2IAsp in Patients With Type 2 Diabetes Mellitus

Beijing Hospital7 sites in 1 country218 target enrollmentMarch 23, 2023

ConditionsType 2 Diabetes Mellitus

InterventionsInsulin Aspart Injection Insulin Degludec and Insulin Aspart Injection

Overview

Phase: Not Applicable
Intervention: Insulin Aspart Injection
Conditions: Type 2 Diabetes Mellitus
Sponsor: Beijing Hospital
Enrollment: 218
Locations: 7
Primary Endpoint: HbA1c
Status: Completed
Last Updated: 5 months ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

In this multicenter, randomized, open-label, parallel-controlled, non-inferiority clinical trial, the efficacy and safety of insulin degludec/insulin aspart (IDegAsp) twice daily will be compared with degludec/insulin aspart (IDegAsp) once daily plus insulin aspart (IAsp) twice daily after 16weeks of treatment in patients with type 2 diabetes mellitus. This trial will enable primary assessment of the clinically relevant endpoint of a change in HbA1c.

Detailed Description

The objective of the current study is to investigate the efficacy and safety of IDegAsp twice daily compared with IDegAsp once daily plus IAsp twice daily for 16 weeks in patients with type 2 diabetes mellitus. The primary endpoint in this study is the change from baseline in HbA1c. Patients with type 2 diabetes who meet the entry criteria are planned for inclusion in this trial. Approximately 224 patients will be enrolled in the study. Patients who qualify will be randomized to IDegAsp group or IDegAsp + IAsp group. Duration of treatment includes 3-week screening period, 16-week treatment observation period and 1-week follow-up.

Registry

clinicaltrials.gov

Start Date

March 23, 2023

End Date

August 15, 2025

Last Updated

5 months ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Beijing Hospital

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•1\. Informed consent has been obtained before any trial-related activities;
•2\. Patients aged 18\~75 years old (including 18 years old and 75 years old);
•3\. Clinical diagnosis of type 2 diabetes ≥ 6 months according to WHO diagnostic criteria before screening;
•4\. Use basal insulin once a day with or without other hypoglycemic drugs for at least 3 months before randomization;
•5\. Glycated hemoglobin between 7.0%\~10.0% within 3 month before randomization (including the critical value);
•6\. Body mass index (BMI)≤40.0kg/m2;

Exclusion Criteria

•1\. Suffering from type 1 diabetes, or special type of diabetes;
•2\. Known premixed insulin or IDegAsp used 3 month before randomization;
•3\. Changes in concomitant medications that are expected to significantly interfere with glucose metabolism;
•4\. Known or suspected subjects are allergic to test drugs, excipients or related similar products and excipients;
•5\. Cardiovascular and cerebrovascular disease, defined as: congestive heart failure (NYHA class III-IV), diagnosis of unstable angina pectoris, stroke and/or myocardial infarction within 6 months before screening; or planned/coronary artery , carotid artery, peripheral artery revascularization;
•6\. According to the judgment of the investigator, repeated hypoglycemia perception impairment and severe hypoglycemia events occurred before screening;
•7\. Abnormal and clinically significant hemoglobin laboratory test results;
•8\. Hepatic insufficiency, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2.5 times the upper limit of the normal range at screening; renal insufficiency, defined as (but not limited to) serum creatinine Levels ≥1.5mg/dL (132umol/L, men) and ≥1.4mg/dL (123umol/L, women), or massive proteinuria (\>2 g/day);
•9\. Uncontrolled/untreated hypertension (systolic blood pressure ≥160mmHg or diastolic blood pressure ≥100mmHg) before randomization;
•10\. Two or more events of ketoacidosis or hyperglycemia and hyperosmolar state requiring hospitalization within 6 months prior to screening, or significant diabetic complications, such as symptomatic autonomic neuropathy, diabetic gastric mildew paralysis, proliferative retinopathy, etc. occured;